Tag: BriaCell Therapeutics Corp.
August 12, 2019
BriaCell Appoints Richard J. Berman to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast... July 23, 2019
BriaCell Announces $350,000 Equity Investment by Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast... May 28, 2019
BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast... May 17, 2019
Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics... May 13, 2019
BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that... April 23, 2019
BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast... April 15, 2019